Neuralstem, Inc (NYSE:CUR) declared fiscal Q1 net loss was $3.6 million, wider than $2.5 million in the same period a year ago. Quarterly loss for fiscal Q1 was $0.05 per share, similar period a year ago.
Thomson Reuters 2 analysts’ survey on average forecasted to announce a loss of $0.05 a share.
Operating loss narrowed to $2.89 million from $2.46 million in the similar period a year ago for the three months period.
Quarterly revenues were $102,500, evaluated against $156,250 in the similar period a year ago.
Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. StemCells Inc (NASDAQ:STEM) fell -2.11% to settle at $1.86, Aastrom Biosciences Inc (NASDAQ:ASTM) moved up +7.14% to end at $0.600 while Charles River Laboratories (NYSE:CRL) jumped +1.35% to finish at $44.31 on Tuesday.
Neuralstem, Inc. (NYSEMKT:CUR) last session’s volume of 340,762 shares was surprisingly higher than its average volume of 337,755 shares. The stock after opening at $1.32 hit high price of $1.33 and then closed at $1.29 by scoring -2.27%.
The liquidity measure in recent quarter results of the company was recorded 4.36 as current ratio. The Company had total cash of $Y million at hand and a book value per share as $Y in the most recent quarter.
The stock’s price volatility was 4.64% for a week and 5.46% for a month as well as price volatility’s Average True Range for 14 days was 0.06 and its beta remained at 1.17.
CUR generated revenue of $0.41 million in the previous twelve months and earned -$10.12 million. Company’s annual sales growth for the past five years was 5.90%.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL